The optimal timing of hepatitis C therapy in transplant eligible patients with child b and c cirrhosis: A cost-effectiveness analysis

Transplantation

Volumn 101, Issue 5, 2017, Pages 987-995

  Tapper, Elliot B ^a   Hughes, Michael S ^a   Buti, Maria ^b   Dufour, Jean Francois ^c   Flamm, Steve ^d   Firdoos, Saima ^a   Curry, Michael P ^a   Afdhal, Nezam H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITY OF BERN   (Switzerland)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE;

COHORT ANALYSIS; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; EFFICACY PARAMETERS; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; LIVER CIRRHOSIS; LIVER GRAFT; MODEL FOR END STAGE LIVER DISEASE SCORE; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; REVIEW; ANALOGS AND DERIVATIVES; COMPLICATION; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DRUG ADMINISTRATION; ECONOMIC MODEL; ECONOMICS; HEPATITIS C, CHRONIC; LIVER TRANSPLANTATION; MULTIMODALITY CANCER THERAPY; TREATMENT OUTCOME; UNITED STATES; VIROLOGY;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG ADMINISTRATION SCHEDULE; FLUORENES; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; RIBAVIRIN; TREATMENT OUTCOME; UNITED STATES; URIDINE MONOPHOSPHATE;

EID: 84982787995     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001400     Document Type: Review

References (45)

1. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370: 1483-1493.
2. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl JMed. 2014;370:1889-1898.
3. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649-659.
4. Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology. 2015;148:100-107. e101.
5. Forns X, CharltonM, Denning J, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015;61:1485-1494.
6. Younossi ZM, Stepanova M, Marcellin P, et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1,-2, and-3 clinical trials. Hepatology. 2015;61:1798-1808.
7. Hoofnagle JH, Sherker AH. Therapy for hepatitis C-the costs of success. N Engl J Med. 2014;370:1552-1553.
8. Liang TJ, Ghany MG. Therapy of hepatitis C-back to the future. N Engl J Med. 2014;370:2043-2047.
9. Pho MT, Linas BP. Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy. Hepatology. 2014;60:12-14.
10. Chhatwal J, Kanwal F, Roberts MS, et al. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015;162:397-406.
11. Linas BP, Barter DM, Morgan JR, et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med. 2015;162:619-629.
12. Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Md. 2015;162:407-419.
13. Veldt BJ, Heathcote EJ,Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677-684.
14. HuninkMGMWM,Wittenberg E, DrummondMF, et al. Decision making in health and medicine: Integrating evidence and values. Cambridge, UK: Cambridge University Press; 2014.
15. Petrou S, Gray A. Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting. BMJ. 2011;342:d1766.
16. Siegel JE, Weinstein MC, Russell LB, et al. Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1339-1341.
17. Wiesner R, Edwards E, Freeman R, et al.Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91-96.
18. Organ Procurement and Transplantation Network. http://optn.transplant. hrsa.gov/latestData/rptData.asp. Accessed 8/9/14.
19. Medici V, Rossaro L, Wegelin JA, et al. The utility of the model for endstage liver disease score: a reliable guide for Liver Transplant candidacy and, for select patients, simultaneous hospice referral. Liver Transpl. 2008; 14:1100-1106.
20. Jain A, Reyes J, Kashyap R, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg. 2000; 232:490-500.
21. Saab S, Hunt DR, StoneMA, et al. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl. 2010;16:748-759.
22. Allen A, KimW, Xiong H, et al. Survival of recipients of livers from donation after circulatory death who are relisted and undergo retransplant for graft failure. Am J Transplant. 2014;14:1120-1128.
23. Red Book. 2014; http://sites.truvenhealth.com/redbook/online/. Accessed November 10, 2015.
24. Bennett WG, Inoue Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med. 1997;127:855-865.
25. Coffin PO, Scott JD, Golden MR, et al. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis. 2012;54:1259-1271.
26. Chong CA, Gulamhussein A, Heathcote EJ, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol. 2003;98: 630-638.
27. Showstack J, Katz PP, Lake JR, et al. Resource utilization in liver transplantation: effects of patient characteristics and clinical practice. JAMA. 1999;281:1381-1386.
28. Hogan C, Lunney J, Gabel J, et al. Medicare beneficiaries' costs of care in the last year of life. Health Aff. 2001;20:188-195.
29. Hoover DR, Crystal S, Kumar R, et al.Medical expenditures during the last year of life: findings from the 1992-1996 Medicare current beneficiary survey. Health Serv Res. 2002;37:1625-1642.
30. Dan AA, Kallman JB, Srivastava R, et al. Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index. Liver Transpl. 2008;14:321-326.
31. Ratcliffe J, Longworth L, Young T, et al. Assessing health-related quality of life pre [ndash] and post [ndash] liver transplantation: a prospective multicenter study. Liver Transpl. 2002;8:263-270.
32. Thein H-H, Krahn M, Kaldor JM, et al. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol. 2005;100:643-651.
33. Younossi ZM, Boparai N, McCormick M, et al. Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol. 2001;96:579-583.
34. Siebert U, Sroczynski G, Rossol S, et al. Cost effectiveness of peginterferon ?-2b plus ribavirin versus interferon ?-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut. 2003;52:425-432.
35. StepanovaM, Nader F,Cure S, et al. Patients' preferences and health utility assessment with SF-6D and EQ-5D in patientswith chronic hepatitis Ctreated with sofosbuvir regimens. Aliment Pharmacol Ther. 2014;40:676-685.
36. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness-the curious resilience of the 50,000-per-QALY threshold. N Engl JMed. 2014;371:796-797.
37. Tapper EB, Sengupta N, Hunink MM, et al. Cost-effective evaluation of nonalcoholic fatty liver disease with NAFLD fibrosis score and vibration controlled transient elastography. AmJGastroenterol. 2015;110:1298-1304.
38. Aghemo A, Donato MF. Sofosbuvir treatment in the pre and post liver transplantation phase: the sooner, the better. Gastroenterology. 2015; 148:13-16.
39. Pho M, Jensen D, MeltzerD, et al. Clinical impact of treatment timing for chronic hepatitis C infection: a decision model. J Viral Hepat. 2015;22:630-638.
40. Leidner AJ, Chesson HW, Xu F, et al. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology. 2015; 61:1860-1869.
41. Chahal HS, Marseille EA, Tice JA, et al. Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population. JAMA Intern Med. 2016;176:65-73.
42. Saab S, Gonzalez YS, Huber C, et al. Cost-effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir + ribavirin for US post-liver transplant recurrent genotype 1 HCV. Liver Int. 2016;36:515-521.
43. Reddy K, Lim JK, Kuo A, et al. All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: report from HCV-TARGET. J Hepatol. 2015;62(suppl 2):S193.
44. Asrani SK, O'Leary JG. The changing liver transplant waitlist: an emerging liver purgatory? Gastroenterology. 2015;3:493-496.
45. CurryMP, O'Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373: 2618-2628.